Advanced glycation end products

National Institute on AgingUS$3.3mNational Institute of Arthritis and Musculoskeletal and Skin DiseasesUS$1.3mNational Institute on Drug AbuseUS$5.5m

• The Value of Medicaid for Adults Ages 50-64

  National Institute on AgingUniversity of Michigan at Ann ArborUS$779.2k2026–2031

• Collagen III differential roles in temporal regulation of tendon healing across ages

  National Institute of Arthritis and Musculoskeletal and Skin DiseasesUniversity of PennsylvaniaUS$329.9k2022–2027

• Serum protein markers along the Alzheimer's disease trajectory in the population-based longitudinal AGES Reykjavik study and their offsprings

  National Institute on AgingIcelandic Heart AssociationUS$549.2k2021–2030

• Role of advanced glycation end products (AGEs) in primary open angle glaucoma

  National Eye InstituteUniversity of Colorado, DenverUS$764.9k2025–2027

• Early Life Stress, DNA Methylation, and Health Disparities across Ages

  National Institute on Minority Health and Health DisparitiesUniversity of Alabama at BirminghamUS$575k2021–2027

• Monitoring the Future: A Cohort-Sequential Panel Study of Drug Use, Ages 19-65

  National Institute on Drug AbuseUniversity of Michigan at Ann ArborUS$2.7m2003–2027

• The role of physiologic and pathologic AGEs on RAGE signaling in IVD degeneration

  National Institute of Arthritis and Musculoskeletal and Skin DiseasesWashington UniversityUS$336.1k2019–2025

• Understanding Cross-National Health Differences at Older Ages and Their Causes

  National Institute on AgingNational Bureau of Economic ResearchUS$608.9k2019–2025

• Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease

  National Institute on AgingRutgers Biomedical and Health SciencesUS$787.2k2023–2025